[go: up one dir, main page]

WO2005035793A3 - Cckar markers and haplotypes associated with extreme weight conditions - Google Patents

Cckar markers and haplotypes associated with extreme weight conditions Download PDF

Info

Publication number
WO2005035793A3
WO2005035793A3 PCT/US2004/033192 US2004033192W WO2005035793A3 WO 2005035793 A3 WO2005035793 A3 WO 2005035793A3 US 2004033192 W US2004033192 W US 2004033192W WO 2005035793 A3 WO2005035793 A3 WO 2005035793A3
Authority
WO
WIPO (PCT)
Prior art keywords
cckar
markers
haplotypes associated
weight conditions
extreme weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/033192
Other languages
French (fr)
Other versions
WO2005035793A2 (en
Inventor
Valur Emilsson
Jeffrey R Gulcher
Gudmundur Bragi Walters
Eric E Schadt
Der Ploeg Leonardus H T Van
Marc L Reitman
John R Lamb
Andreas W Sailer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Rosetta Inpharmatics LLC
Merck and Co Inc
Original Assignee
Decode Genetics ehf
Rosetta Inpharmatics LLC
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf, Rosetta Inpharmatics LLC, Merck and Co Inc filed Critical Decode Genetics ehf
Publication of WO2005035793A2 publication Critical patent/WO2005035793A2/en
Publication of WO2005035793A3 publication Critical patent/WO2005035793A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for diagnosis of obesity or a susceptibility or resistance to obesity based on detection of at risk haplotypes associated with human Cholecystokinin Type A Receptor gene are disclosed.
PCT/US2004/033192 2003-10-09 2004-10-08 Cckar markers and haplotypes associated with extreme weight conditions Ceased WO2005035793A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50992303P 2003-10-09 2003-10-09
US60/509,923 2003-10-09

Publications (2)

Publication Number Publication Date
WO2005035793A2 WO2005035793A2 (en) 2005-04-21
WO2005035793A3 true WO2005035793A3 (en) 2005-06-09

Family

ID=34435037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033192 Ceased WO2005035793A2 (en) 2003-10-09 2004-10-08 Cckar markers and haplotypes associated with extreme weight conditions

Country Status (1)

Country Link
WO (1) WO2005035793A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022004142A (en) 2019-10-07 2022-09-21 Kallyope Inc Gpr119 agonists.
TW202140440A (en) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40 agonists

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09140398A (en) * 1995-11-21 1997-06-03 Shionogi & Co Ltd Detection of ii type diabetic gene
WO2000068209A2 (en) * 1999-05-06 2000-11-16 Glaxo Group Limited 1,5-benzodiazepine derivatives as cck-a receptor agonists
JP2002017369A (en) * 2000-07-07 2002-01-22 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Cholecystokinin A receptor gene polymorphism for detection of risk factors for obesity
WO2002027008A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Promoter sequences
WO2002034743A1 (en) * 2000-10-26 2002-05-02 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
WO2003063828A1 (en) * 2002-02-01 2003-08-07 Arizona Health Consulting Group, Llc Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer
JP2004105145A (en) * 2002-09-20 2004-04-08 Japan Science & Technology Corp A simple method to determine the genetic risk of cardiovascular disease, obesity and lifestyle-related diseases
WO2004061616A2 (en) * 2002-12-27 2004-07-22 Rosetta Inpharmatics Llc Computer systems and methods for associating genes with traits using cross species data

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09140398A (en) * 1995-11-21 1997-06-03 Shionogi & Co Ltd Detection of ii type diabetic gene
WO2000068209A2 (en) * 1999-05-06 2000-11-16 Glaxo Group Limited 1,5-benzodiazepine derivatives as cck-a receptor agonists
JP2002017369A (en) * 2000-07-07 2002-01-22 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Cholecystokinin A receptor gene polymorphism for detection of risk factors for obesity
WO2002027008A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Promoter sequences
WO2002034743A1 (en) * 2000-10-26 2002-05-02 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
WO2003063828A1 (en) * 2002-02-01 2003-08-07 Arizona Health Consulting Group, Llc Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer
JP2004105145A (en) * 2002-09-20 2004-04-08 Japan Science & Technology Corp A simple method to determine the genetic risk of cardiovascular disease, obesity and lifestyle-related diseases
WO2004061616A2 (en) * 2002-12-27 2004-07-22 Rosetta Inpharmatics Llc Computer systems and methods for associating genes with traits using cross species data

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FUNAKOSHI A ET AL: "Gene structure of human cholecystokinin (CCK) type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 466, no. 2-3, 28 January 2000 (2000-01-28), pages 264 - 266, XP004260881, ISSN: 0014-5793 *
INOUE H ET AL: "Human Cholecystokinin Type A Receptor Gene: Cytogenetic Localization, Physical Mapping, and Identification of Two Missense Variants in Patients with Obesity and Non-Insulin-Dependent Diabetes Mellitus (NIDDM)", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 42, no. 2, 1 June 1997 (1997-06-01), pages 331 - 335, XP004459301, ISSN: 0888-7543 *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 10 31 October 1997 (1997-10-31) *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 05 3 May 2002 (2002-05-03) *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *
TAKATA YUTAKA ET AL: "Promoter analysis of human cholecystokinin type-A receptor gene.", JOURNAL OF GASTROENTEROLOGY, vol. 37, no. 10, October 2002 (2002-10-01), pages 815 - 820, XP002323108, ISSN: 0944-1174 *

Also Published As

Publication number Publication date
WO2005035793A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
WO2008118258A3 (en) Genemap of the human genes associated with adhd
WO2008067195A8 (en) Genemap of the human genes associated with crohn's disease
WO2008112177A8 (en) Genemap of the human genes associated with schizophrenia
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2008016356A3 (en) Genemap of the human genes associated with psoriasis
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007025085A8 (en) Genemap of the human genes associated with crohn's disease
WO2009026116A3 (en) Genemap of the human genes associated with longevity
EP2570498A3 (en) Genetic markers of mental illness
WO2006047787A3 (en) Method for monitoring disease progression or recurrence
EP2581459A3 (en) Genetic markers of mental illness
WO2006084195A3 (en) Personal assessment including familial risk analysis for personalized disease prevention plan
WO2006138696A3 (en) Genemap of the human genes associated with longevity
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2008154352A3 (en) Genetic markers associated with endometriosis and use thereof
EP1994170A4 (en) Kits and method for detecting human papilloma virus with oligo nucleotide bead array
WO2008085601A3 (en) Genemap of the human genes associated with asthma disease
WO2009058851A3 (en) Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
WO2009039244A3 (en) Genemap of the human genes associated with crohn's disease
EP1685149A4 (en) Primers, methods and kits for detecting killer-cell immunoglobulin-like receptor alleles
WO2005035793A3 (en) Cckar markers and haplotypes associated with extreme weight conditions
WO2008123901A3 (en) Genemap of the human genes associated with endometriosis
WO2007067719A3 (en) Diagnosing human diseases by detecting dna methylation changes
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase